Lung cancer is the most common cancer in the world. In addition to the geographical and sex-specific differences in the incidence, mortality, and survival rates of lung cancer, growing evidence suggests that racial and ethnic differences exist.
Methods
We reviewed published data related to racial and ethnic differences in lung cancer.
Results
Current knowledge and substantive findings related to racial and ethnic differences in lung cancer were summarized, focusing on incidence, mortality, survival, cigarette smoking, prevention and early detection, and genomics. Systems-level and health care professional–related issues likely to contribute to specific racial and ethnic health disparities were also reviewed to provide possible suggestions for future strategies to reduce the disproportionate burden of lung cancer.
Conclusions
Although lung carcinogenesis is a multifactorial process driven by exogenous exposures, genetic variations, and an accumulation of somatic genetic events, it appears to have racial and ethnic differences that in turn impact the observed epidemiological differences in rates of incidence, mortality, and survival.
International Agency for Research on Cancer; World Health Organization.GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012.http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed August 29, 2016.
FarjahF., WoodD.E., YanezN.D.3rd. Racial disparities among patients with lung cancer who were recommended operative therapy.Arch Surg.2009; 144(1): 14–18.
5.
SteeleC.B., PisuM., RichardsonL.C.Urban/rural patterns in receipt of treatment for non-small cell lung cancer among black and white Medicare beneficiaries, 2000-2003.J Natl Med Assoc.2011; 103(8): 711–718.
6.
EsnaolaN.F., GebregziabherM., KnottK.Underuse of surgical resection for localized, non-small cell lung cancer among whites and African Americans in South Carolina.Ann Thorac Surg.2008; 86(1): 220–226.
7.
van RynM.Research on the provider contribution to race/ethnicity disparities in medical care.Med Care.2002; 40(1 suppl): I140–I151.
8.
UnderwoodJ.M., TownsendJ.S., TaiE.Racial and regional disparities in lung cancer incidence.Cancer.2012; 118(7): 1910–1918.
9.
YangR., CheungM.C., ByrneM.M.Do racial or socioeconomic disparities exist in lung cancer treatment?Cancer.2010; 116(10): 2437–2447.
10.
HowladerN., NooneA.M., KrapchoM., eds. SEER Cancer Statistics Review, 1975-2012.Bethesda, MD: National Cancer Institute. Based on November 2014 SEER data submission, posted to the SEER web site, April 2015. http://seer.cancer.gov/csr/1975_2012. Accessed June 30, 2016.
11.
Centers for Disease Control and Prevention.Racial/ethnic disparities and geographic differences in lung cancer incidence: 38 states and the District of Columbia, 1998-2006.MMWR Morb Mortal Wkly Rep.2010; 59(44): 1434–1438.
12.
SankarP., ChoM.K.Genetics. Toward a new vocabulary of human genetic variation.Science.2002; 298(5597): 1337–1338.
13.
WitzigR.The medicalization of race: scientific legitimization of a flawed social construct.Ann Intern Med.1996; 125(8): 675–679.
IslamiF., TorreL.A., JemalA.Global trends of lung cancer mortality and smoking prevalence.Transl Lung Cancer Res.2015; 4(4): 327–338.
16.
HarrisK., KhachaturovaI., AzabB.Small cell lung cancer doubling time and its effect on clinical presentation: a concise review.Clin Med Insights Oncol.2012; 6: 199–203.
17.
SchabathM.B., ThompsonZ.J., GrayJ.E.Temporal trends in demographics and overall survival of non-small-cell lung cancer patients at Moffitt Cancer Center from 1986 to 2008.Cancer Control.2014; 21(1): 51–56.
18.
KachrooS., TongL., SpitzM.R.Trends in prevalence of prognostic factors and survival in lung cancer patients from 1985 to 2004 at a tertiary care center.Cancer Detect Prev.2008; 32(2): 101–108.
19.
Dela CruzC.S., TanoueL.T., MatthayR.A.Lung cancer: epidemiology, etiology, and prevention.Clin Chest Med.2011; 32(4): 605–644.
20.
BirimO., KappeteinA.P., van KlaverenR.J.Prognostic factors in non-small cell lung cancer surgery.Eur J Surg Oncol.2006; 32(1): 12–23.
PaesmansM., SculierJ.P., LecomteJ.Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years.Cancer.2000; 89(3): 523–533.
23.
SpiegelmanD., MaurerL.H., WareJ.H.Prognostic factors in small-cell carcinoma of the lung: an analysis of 1,521 patients.J Clin Oncol.1989; 7(3): 344–354.
24.
AlbainK.S., CrowleyJ.J., LeBlancM.Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base.J Clin Oncol.1990; 8(9): 1563–1574.
25.
OsterlindK., AndersenP.K.Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation.Cancer Res.1986; 46(8): 4189–4194.
26.
SchabathM.B., NguyenA., WilsonP.Temporal trends from 1986 to 2008 in overall survival of small cell lung cancer patients.Lung Cancer.2014; 86(1): 14–21.
27.
SantarpiaM., GiovannettiE., RolfoC.Recent developments in the use of immunotherapy in non-small cell lung cancer.Expert Rev Respir Med.2016; 10(7): 781–798.
28.
TchekmedyianN., GrayJ.E., CreelanB.C.Propelling immunotherapy combinations into the clinic.Oncology (Williston Park).2015; 29(12): pii: 214814.
29.
BrahmerJ.R.Harnessing the immune system for the treatment of non-small-cell lung cancer.J Clin Oncol.2013; 31(8): 1021–1028.
30.
MargolisM.L., ChristieJ.D., SilvestriG.A.Racial differences pertaining to a belief about lung cancer surgery: results of a multicenter survey.Ann Intern Med.2003; 139(7): 558–563.
31.
ShugarmanL.R., MackK., SorberoM.E.Race and sex differences in the receipt of timely and appropriate lung cancer treatment.Med Care.2009; 47(7): 774–781.
32.
ZulligL.L., CarpenterW.R., ProvenzaleD.T.The association of race with timeliness of care and survival among Veterans Affairs health care system patients with late-stage non-small cell lung cancer.Cancer Manag Res.2013; 5: 157–163.
33.
HowingtonJ.A., BlumM.G., ChangA.C.Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.Chest.2013; 143(5 suppl): e278S–e313S.
34.
LinJ.J., MhangoG., WallM.M.Cultural factors associated with racial disparities in lung cancer care.Ann Am Thorac Soc.2014; 11(4): 489–495.
35.
HardyD., LiuC.C., XiaR.Racial disparities and treatment trends in a large cohort of elderly black and white patients with non-small cell lung cancer.Cancer.2009; 115(10): 2199–2211.
36.
HardyD., XiaR., LiuC.C.Racial disparities and survival for non-small-cell lung cancer in a large cohort of black and white elderly patients.Cancer.2009; 115(20): 4807–4818.
37.
US Department of Health and Human Services.The Health Consequences of Smoking: 50 Years Of Progress. A Report of the Surgeon General.Atlanta, GA: US Department of Health and Human Services; Centers for Disease Control and Prevention; National Center for Chronic Disease Prevention and Health Promotion; Office on Smoking and Health; 2014.
38.
CarterB.D., FreedmanN.D., JacobsE.J.Smoking and mortality: beyond established causes.N Engl J Med.2015; 372(22): 2170.
39.
PeschB., KendziaB., GustavssonP.Cigarette smoking and lung cancer: relative risk estimates for the major histological types from a pooled analysis of case-control studies.Int J Cancer.2012; 131(5): 1210–1219.
40.
US Department of Health and Human Services.How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General.Atlanta: US Department of Health and Human Services; Centers for Disease Control and Prevention; National Center for Chronic Disease Prevention and Health Promotion; Office on Smoking and Health; 2010.
41.
JamalA., HomaD.M., O'ConnorE.Current cigarette smoking among adults: United States, 2005-2014.MMWR Morb Mortal Wkly Rep.2015; 64(44): 1233–1240.
42.
Centers for Disease Control and Prevention.Cigarette smoking among adults: United States, 2006.MMWR Morb Mortal Wkly Rep.2007; 56(44): 1157–1161.
43.
JamalA., AgakuI.T., O'ConnorE.Current cigarette smoking among adults: United States, 2005-2013.MMWR Morb Mortal Wkly Rep.2014; 63(47): 1108–1112.
44.
HaimanC.A., StramD.O., WilkensL.R.Ethnic and racial differences in the smoking-related risk of lung cancer.N Engl J Med.2006; 354(4): 333–342.
45.
DriscollT., NelsonD.I., SteenlandK.The global burden of disease due to occupational carcinogens.Am J Ind Med.2005; 48(6): 419–431.
46.
AlbergA.J., BrockM.V., FordJ.G.Epidemiology of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.Chest.2013; 143(5 suppl): e1S–e29S.
47.
BrintonL.A., GierachG.L., AndayaA.Reproductive and hormonal factors and lung cancer risk in the NIH-AARP Diet and Health Study cohort.Cancer Epidemiol Biomarkers Prev.2011; 20(5): 900–911.
48.
YaoY., GuX., ZhuJ.Hormone replacement therapy in females can decrease the risk of lung cancer: a meta-analysis.PLoS One.2013; 8(8): e71236.
49.
YangY., DongJ., SunK.Obesity and incidence of lung cancer: a meta-analysis.Int J Cancer.2013; 132(5): 1162–1169.
50.
SmithL., BrintonL.A., SpitzM.R.Body mass index and risk of lung cancer among never, former, and current smokers.J Natl Cancer Inst.2012; 104(10): 778–789.
51.
WuS.H., LiuZ.Soy food consumption and lung cancer risk: a meta-analysis using a common measure across studies.Nutr Cancer.2013; 65(5): 625–632.
52.
WuQ.J., XieL., ZhengW.Cruciferous vegetables consumption and the risk of female lung cancer: a prospective study and a metaanalysis.Ann Oncol.2013; 24(7): 1918–1924.
53.
SongJ., SuH., WangB.L.Fish consumption and lung cancer risk: systematic review and meta-analysis.Nutr Cancer.2014; 66(4): 539–549.
SlatoreC.G., BaumannC., PappasM.Smoking behaviors among patients receiving computed tomography for lung cancer screening. Systematic review in support of the U.S. Preventive Services Task Force.Ann Am Thorac Soc.2014; 11(4): 619–627.
TannerN.T., GebregziabherM., Hughes HalbertC.Racial differences in outcomes within the National Lung Screening Trial. Implications for widespread implementation.Am J Respir Crit Care Med.2015; 192(2): 200–208.
58.
KumarP., GareenI.F., LathanC.Racial differences in tobacco cessation and treatment usage after lung screening: an examination of the National Lung Screening Trial.Oncologist.2016; 21(1): 40–49.
59.
PinskyP.F., ZhuC.S., KramerB.S.Lung cancer risk by years since quitting in 30+ pack year smokers.J Med Screen.2015; 22(3): 151–157.
60.
Clinical Lung Cancer Genome Project (CLCGP); Network Genomic Medicine (NGM). A genomics-based classification of human lung tumors.Sci Transl Med.2013; 5(209): 209ra153.
CressW.D., ChiapporiA., SantiagoP.Lung cancer mutations and use of targeted agents in Hispanics.Rev Recent Clin Trials.2014; 9(4): 225–232.
63.
PolitiK., HerbstR.S.Lung cancer in the era of precision medicine.Clin Cancer Res.2015; 21(10): 2213–2220.
64.
Bollig-FischerA., ChenW., GadgeelS.M.Racial diversity of actionable mutations in non-small cell lung cancer.J Thorac Oncol.2015; 10(2): 250–255.
65.
ZhouW., ChristianiD.C.East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians.Chin J Cancer.2011; 30(5): 287–292.
66.
da Cunha SantosG., ShepherdF.A.EGFR mutations and lung cancer.Annu Rev Pathol.2011; 6: 49–69.
67.
PaoW., MillerV., ZakowskiM.EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib.Proc Natl Acad Sci U S A.2004; 101(36): 13306–13311.
68.
PaezJ.G., JanneP.A., LeeJ.C.EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.Science.2004; 304(5676): 1497–1500.
69.
SohJ., OkumuraN., LockwoodW.W.Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells.PLoS One.2009; 4(10): e7464.
ShiY., LiJ., ZhangS.Molecular epidemiology of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology - mainland China subset analysis of the PIONEER study.PLoS One.2015; 10(11): e0143515.
72.
DoganS., ShenR., AngD.C.Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers.Clin Cancer Res.2012; 18(22): 6169–6177.
73.
VargheseA.M., SimaC.S., ChaftJ.E.Lungs don't forget: comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers.J Thorac Oncol.2013; 8(1): 123–125.
74.
ShigematsuH., LinL., TakahashiT.Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.J Natl Cancer Inst.2005; 97(5): 339–346.
75.
YangJ.C., WuY.L., ChanV.Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS).Lung Cancer.2014; 83(2): 174–181.
76.
MokT.S., WuY.L., ThongprasertS.Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.N Engl J Med.2009; 361(10): 947–957.
77.
ZhuC.Q., da Cunha SantosG., DingK., SakuradaA.Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.J Clin Oncol.2008; 26(26): 4268–4275.
78.
HanB., TjulandinS., HagiwaraK.Determining the prevalence of EGFR mutations in Asian and Russian patients (pts) with advanced non-small-cell lung cancer (aNSCLC) of adenocarcinoma (ADC) and non-ADC histology: Ignite Study.Ann Oncol.2015; 26(suppl 1): 29–44.
79.
YangS.H., MechanicL.E., YangP.Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer.Clin Cancer Res.2005; 11(6): 2106–2110.
80.
LeidnerR.S., FuP., CliffordB.Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer.J Clin Oncol.2009; 27(33): 5620–5626.
81.
RielyG.J., PaoW., PhamD.Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.Clin Cancer Res.2006; 12(3 pt 1): 839–844.
82.
CoteM.L., HaddadR., EdwardsD.J.Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer.J Thorac Oncol.2011; 6(3): 627–630.
83.
ReinersmanJ.M., JohnsonM.L., RielyG.J.Frequency of EGFR and KRAS mutations in lung adenocarcinomas in African Americans.J Thorac Oncol.2011; 6(1): 28–31.
84.
ArrietaO., CardonaA.F., Federico BramugliaG.Genotyping non-small cell lung cancer (NSCLC) in Latin America.J Thorac Oncol.2011; 6(11): 1955–1959.
85.
Corrales-RodriguezL., AbbasJ., Ramos-EsquivelA.Immunohistochemistry as a predictor of EGFR mutations: a retrospective case-control study.J Thorac Oncol.2014; 9(9 suppl 3): S176.
86.
Rojas VigottR., Ugalde GamboaL., Rojas SolanoJ.Thoracic oncology clinic: our first 200 cases. San José, Costa Rica.J Thorac Oncol.2014; 9(9 suppl 3): S182.
87.
Castillo-FernandezO., ArauzE., CabrejaA.EGFR mutation and outcomes in patients with metastatic NSCLC treated with erlotinib at Instituto Oncologico Nacional, Panama.J Thorac Oncol.2014; 9(9 suppl 3): S189.
88.
RielyG.J., MarksJ., PaoW.KRAS mutations in non-small cell lung cancer.Proc Am Thorac Soc.2009; 6(2): 201–205.
89.
AdjeiA.A.Blocking oncogenic Ras signaling for cancer therapy.J Natl Cancer Inst.2001; 93(14): 1062–1074.
90.
CoxA.D., DerC.J.Ras history: the saga continues.Small GTPases.2010; 1(1): 2–27.
91.
CastellanoE., SantosE.Functional specificity of ras isoforms: so similar but so different.Genes Cancer.2011; 2(3): 216–231.
CalifanoR., LandiL., CappuzzoF.Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer.Drugs.2012; 72(suppl 1): 28–36.
95.
MengD., YuanM., LiX.Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with metaanalysis.Lung Cancer.2013; 81(1): 1–10.
96.
RielyG.J., KrisM.G., RosenbaumD.Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.Clin Cancer Res.2008; 14(18): 5731–5734.
97.
SunY., RenY., FangZ.Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.J Clin Oncol.2010; 28(30): 4616–4620.
98.
El-TelbanyA., MaP.C.Cancer genes in lung cancer: racial disparities: are there any?Genes Cancer.2012; 3(7-8): 467–480.
99.
BaumlJ., MickR., ZhangY.Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: do disparities exist?Lung Cancer.2013; 81(3): 347–353.
100.
McQuittyE., ZhangW., HendricksonH.Lung adenocarcinoma biomarker incidence in Hispanic versus non-Hispanic white patients.Arch Pathol Lab Med.2014; 138(3): 390–394.
101.
ShawR.J., KosmatkaM., BardeesyN.The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress.Proc Natl Acad Sci U S A.2004; 101(10): 3329–3335.
102.
CaoY., LiH., LiuH.The serine/threonine kinase LKB1 controls thymocyte survival through regulation of AMPK activation and Bcl-XL expression.Cell Res.2010; 20(1): 99–108.
103.
GaoY., GeG., JiH.LKB1 in lung cancerigenesis: a serine/threonine kinase as tumor suppressor.Protein Cell.2011; 2(2): 99–107.
LimW., HearleN., ShahB.Further observations on LKB1/STK11 status and cancer risk in Peutz-Jeghers syndrome.Br J Cancer.2003; 89(2): 308–313.
106.
Sanchez-CespedesM., ParrellaP., EstellerM.Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung.Cancer Res.2002; 62(13): 3659–3662.
107.
ShahU., SharplessN.E., HayesD.N.LKB1 and lung cancer: more than the usual suspects.Cancer Res.2008; 68(10): 3562–3565.
108.
Sanchez-CespedesM.The role of LKB1 in lung cancer.Fam Cancer.2011; 10(3): 447–453.
109.
MatsumotoS., IwakawaR., TakahashiK.Prevalence and specificity of LKB1 genetic alterations in lung cancers.Oncogene.2007; 26(40): 5911–5918.
110.
JiH., RamseyM.R., HayesD.N.LKB1 modulates lung cancer differentiation and metastasis.Nature.2007; 448(7155): 807–810.
111.
O'NeillG.M., SeoS., SerebriiskiiI.G.A new central scaffold for metastasis: parsing HEF1/Cas-L/NEDD9.Cancer Res.2007; 67(19): 8975–8979.
112.
GaoY., XiaoQ., MaH.LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling.Proc Natl Acad Sci U S A.2010; 107(44): 18892–18897.
Sanchez-CespedesM.A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome.Oncogene.2007; 26(57): 7825–7832.
115.
KoivunenJ.P., KimJ., LeeJ.Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients.Br J Cancer.2008; 99(2): 245–252.
116.
OnozatoR., KosakaT., AchiwaH.LKB1 gene mutations in Japanese lung cancer patients.Cancer Sci.2007; 98(11): 1747–1751.
117.
GaoB., SunY., ZhangJ.Spectrum of LKB1, EGFR, and KRAS mutations in Chinese lung adenocarcinomas.J Thorac Oncol.2010 Aug;5(8): 1130–1135.
118.
SunY.H., RenY., FangZ.Y.Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.J Clin Oncol.2010; 28(30): 4616–4620.
119.
SchabathM.B., WelshE.A., FulpW.J.Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma.Oncogene.2016; 35(24): 3209–3216.
120.
ForcetC., Etienne-MannevilleS., GaudeH.Functional analysis of Peutz-Jeghers mutations reveals that the LKB1 C-terminal region exerts a crucial role in regulating both the AMPK pathway and the cell polarity.Hum Mol Genet.2005; 14(10): 1283–1292.
121.
Sánchez-TorresJ.M., ViteriS., MolinaM.A.BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors.Transl Lung Cancer Res.2013; 2(3): 244–250.
122.
DaviesH., BignellG.R., CoxC.Mutations of the BRAF gene in human cancer.Nature.2002; 417(6892): 949–954.
123.
NaokiK., ChenT.H., RichardsW.G.Missense mutations of the BRAF gene in human lung adenocarcinoma.Cancer Res.2002; 62(23): 7001–7003.
124.
BroseM.S., VolpeP., FeldmanM.BRAF and RAS mutations in human lung cancer and melanoma.Cancer Res.2002; 62(23): 6997–7000.
125.
MarchettiA., FelicioniL., MalatestaS.Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations.J Clin Oncol.2011; 29(26): 3574–3579.
126.
SamuelsY., WangZ., BardelliA.High frequency of mutations of the PIK3CA gene in human cancers.Science.2004; 304(5670): 554.
127.
KawanoO., SasakiH., EndoK.PIK3CA mutation status in Japanese lung cancer patients.Lung Cancer.2006; 54(2): 209–215.
128.
SodaM., ChoiY.L., EnomotoM.Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.Nature.2007; 448(7153): 561–566.
129.
KoivunenJ.P., MermelC., ZejnullahuK.EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.Clin Cancer Res.2008; 14(13): 4275–4283.
130.
WongD.W., LeungE.L., SoK.K.The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.Cancer.2009; 115(8): 1723–1733.
131.
InamuraK., TakeuchiK., TogashiY.EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.J Thorac Oncol.2008; 3(1): 13–17.
132.
InamuraK., TakeuchiK., TogashiY.EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.Mod Pathol.2009; 22(4): 508–515.
133.
RenS., KuangP., ZhengL.Analysis of driver mutations in female non-smoker Asian patients with pulmonary adenocarcinoma.Cell Biochem Biophys.2012; 64(2): 155–160.
134.
LiC., FangR., SunY.Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers.PLoS One.2011; 6(11): e28204.
135.
KimH.R., ShimH.S., ChungJ.H.Distinct clinical features and outcomes in never-smokers with non-small cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.Cancer.2012; 118(3): 729–739.
136.
ShinmuraK., KageyamaS., TaoH.EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas.Lung Cancer.2008; 61(2): 163–169.
137.
MartelliM.P., SozziG., HernandezL.EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues.Am J Pathol.2009; 174(2): 661–670.
